Atsena Therapeutics Appoints Kenji Fujita, MD, as Chief Medical Officer DURHAM, N.C., June 14, 2021 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors Company expands board of directors and plans to build out team DURHAM, N.C....

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis Therapy currently being evaluated in Phase I/II clinical studyCompany formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness ...